S&P 500
5,921.54
+2.0%
+$118.72
DJI
42,343.65
+1.8%
+$740.58
NASDAQ
19,199.16
+2.5%
+$461.96
Bitcoin
109,873.00
+0.7%
+785.77
AAPL
$200.00
+2.4%
+$4.73
AMZN
$205.78
+2.4%
+$4.79
GOOG
$173.90
+2.5%
+$4.32
META
$641.62
+2.3%
+$14.56
MSFT
$460.09
+2.2%
+$9.91
NVDA
$135.32
+3.1%
+$4.03
TSLA
$361.87
+6.6%
+$22.53
Lexeo Therapeutics (NASDAQ: LXEO)
$2.68
(-5.0%)
-$0.14
Price as of May 27, 2025, 3:58 p.m. ET
Lexeo Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Lexeo Therapeutics Company Info
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.